UBS AM
AXDX

UBS AM’s Accelerate Diagnostics AXDX Stock Holding History

UBS AM’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,357
Closed -$48.3K – 2695
2022
Q1 		$48.3K Hold
3,357
– – ﹤0.01% 2765
2021
Q4 		$175K Buy
3,357
+137
+4% +$7.63K ﹤0.01% 2779
2021
Q3 		$188K Buy
3,220
+32
+1% +$2.09K ﹤0.01% 2696
2021
Q2 		$257K Buy
3,188
+93
+3% +$7.39K ﹤0.01% 2674
2021
Q1 		$258K Hold
3,095
– – ﹤0.01% 2516
2020
Q4 		$235K Hold
3,095
– – ﹤0.01% 2470
2020
Q3 		$330K Buy
3,095
+1,595
+106% +$221K ﹤0.01% 2283
2020
Q2 		$227K Sell
1,500
-1,044
-41% -$103K ﹤0.01% 2352
2020
Q1 		$212K Sell
2,544
-172
-6% -$24.2K ﹤0.01% 2255
2019
Q4 		$459K Sell
2,716
-6
-0.2% -$990 ﹤0.01% 2270
2019
Q3 		$505K Buy
2,722
+1,152
+73% +$223K ﹤0.01% 2294
2019
Q2 		$359K Hold
1,570
– – ﹤0.01% 2345
2019
Q1 		$330K Hold
1,570
– – ﹤0.01% 2282
2018
Q4 		$181K Hold
1,570
– – ﹤0.01% 2418
2018
Q3 		$360K Hold
1,570
– – ﹤0.01% 2222
2018
Q2 		$350K Buy
1,570
+680
+76% +$152K ﹤0.01% 2242
2018
Q1 		$203K Hold
890
– – ﹤0.01% 2369
2017
Q4 		$233K Buy
+890
New +$209K ﹤0.01% 2235
2017
Q3 		– Sell
-890
Closed -$243K – 2535
2017
Q2 		$243K Buy
+890
New +$241K ﹤0.01% 2126
2016
Q4 		– Sell
-1,710
Closed -$466K – 2514
2016
Q3 		$466K Hold
1,710
– – ﹤0.01% 2018
2016
Q2 		$246K Hold
1,710
– – ﹤0.01% 2322
2016
Q1 		$246K Hold
1,710
– – ﹤0.01% 2318
2015
Q4 		$367K Hold
1,710
– – ﹤0.01% 2229
2015
Q3 		$277K Buy
+1,710
New +$370K ﹤0.01% 2325

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

UBS AM's AXDX Position: Q2 2022 in Review

UBS AM sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 3,357 shares — an estimated $48.3K sold.

UBS AM first reported a position in AXDX in Q3 2015 and held it in 24 quarters. The position peaked at $505K in Q3 2019. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

  • UBS AM reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
  • UBS AM sold 3,357 Accelerate Diagnostics shares in Q2 2022, an estimated $48.3K.
  • UBS AM first reported a position in Accelerate Diagnostics in Q3 2015 and held it in 24 quarters.
  • UBS AM's Accelerate Diagnostics position peaked at $505K in Q3 2019.
  • 74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on UBS AM's 13F filing for Q2 2022, filed 12 Aug 2022.